Results 81 to 90 of about 1,168 (116)

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. [PDF]

open access: yesTrials, 2017
Collett L   +13 more
europepmc   +1 more source

The regulatory capacity of B cells directs the aggressiveness of CLL. [PDF]

open access: yesOncoimmunology, 2019
Mohr A   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy